How to Buy Oncternal Therapeutics Stock
Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.
Oncternal Therapeutics stock last closed at $8.77, up 2.51% from the previous day, and has increased 32.8% in one year. It has overperformed other stocks in the Biotechnology industry by 0.56 percentage points. Oncternal Therapeutics stock is currently +57.47% from its 52-week low of $5.57, and -33.3% from its 52-week high of $13.14.
There are currently 2.96M shares of ONCT outstanding. The market capitalization of ONCT is $25.94M. In the last 24 hours, 955 ONCT shares were traded.
How to Buy Oncternal Therapeutics Stock
Wondering how to invest in Oncternal Therapeutics stock? Here's how.
- Choose where to buy Oncternal Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you decide where to buy Oncternal Therapeutics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Pick your payment method and add your information.
- Evaluate Oncternal Therapeutics stock: The Oncternal Therapeutics ticker symbol is ONCT. Is Oncternal Therapeutics stock a good investment? Should you buy shares of ONCT? How do ONCT's underlying business fundamentals look? Do top analysts think Oncternal Therapeutics is a good buy? Why has ONCT's stock price moved recently? (Hint: Our stock market research website can help you understand if ONCT is a good stock to buy).
- Place your ONCT trade: Decide if you will purchase ONCT shares at the current market price or use a limit order to buy ONCT stock at a given price.
- Get the latest scoop on your investment in ONCT: Create a watchlist to keep tabs on your new investment in Oncternal Therapeutics stock.
Step 1: Choose where to buy Oncternal Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy ONCT shares.
Our preferred brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Industrials, New York to Shanghai — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by signing up for an account with eToro now.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal details so you can buy ONCT stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to open a new brokerage account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've finished signing up on the greatest app to buy stocks, you can securely and quickly fund your account:
Check out this video walkthrough if you need help depositing money into your investment account.
Step 4: Evaluate Oncternal Therapeutics stock
Once you have identified the best place to buy Oncternal Therapeutics stock, it's critical to research their stock before you buy, so you actually wrap your head around the risk as well as the upside.
Oncternal Therapeutics shares quick numbers
ONCT Zen Score
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis quickly.
You can see all of the due diligence checks on ONCT's stock page.
Is ONCT stock undervalued?
Investors use many financial metrics, analyses, models, and charts to gauge ONCT's intrinsic value.
Using relative valuations methods:
- ONCT could be undervalued based on its P/B ratio of 0.86x, relative to Biotechnology industry P/B ratio of 5.93x
You can do more valuation analysis on ONCT's stock here.
ONCT Financials at a glance
Positive Health Checks:
- There are more short-term assets than long-term liabilities on the ONCT balance sheet.
- Total ONCT debt is lower than 5 years ago, relative to shareholder equity.
- ONCT has a low debt to equity ratio of 0.22.
- There are more short-term assets than short-term liabilities on the ONCT balance sheet.
- ONCT has cash burn of 32164000. It has enough cash and short-term investments to cover this for at least one year.
Negative Health Checks:
- ONCT has $34.26M in cash and short term investments. This is not enough to cover its annual cash burn of $32.16M.
- ONCT profit margin has gone down from -2,964.4% to -5,029.2% in the past year.
Do analysts think it's a good time to buy Oncternal Therapeutics stock
Out of 2 sell side analysts who give recommendations on ONCT, the consensus analyst rating on ONCT is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are forecasting on the Oncternal Therapeutics stock forecast page.
ONCT Momentum
ONCT Performance Numbers
Last year, ONCT revenue was $785.00k. Over the last five year, ONCT's revenue has gone up by -20.81% per year. This was slower than the Biotechnology industry average of 28.88%.
You can analyze ONCT's earnings and revenue performance here.
Are ONCT executives and large shareholders buying or selling the stock?
In the last year, insiders at ONCT have sold more shares than they have bought.
Robert James Wills, Director of ONCT, was the latest ONCT insider to buy. They bought $27,653.65 worth of ONCT shares on Apr 8, 2024.
Research more about who owns ONCT shares here.
Does ONCT stock generate passive income?
No, Oncternal Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about ONCT?
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your ONCT trade
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at an exact dollar amount limit, use a limit order.
Hit the Open Trade button and your broker will place your order.
If you want additional info about investing in stocks on eToro, click the helpful video below:
Step 6: Get the latest scoop on your investment in ONCT
Now that you own some ONCT stock, you'll want to stay up-to-date on your new investment.
Add ONCT to a watchlist to get alerted to the latest events about your ONCT stock.
ONCT Feed
How to Buy Stock in Oncternal Therapeutics
To reiterate, here are the 6 steps to buy Oncternal Therapeutics stock:
- Choose where to buy Oncternal Therapeutics stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Evaluate Oncternal Therapeutics stock
- Place your ONCT trade
- Get the latest scoop on your investment in ONCT
If you need a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest scoop on your investment in Oncternal Therapeutics, click the button below.
More "How To" Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.